U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT06881888) titled 'Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema' on March 05.
Brief Summary: Treatment of diabetic retinopathy (DR) and diabetic macula edema has included panretinal photocoagulation and intra ocular injections of anti-vascular endothelial growth factors (anti-VEGF) agents and steroids. Anti-VEGF therapy is currently the first-line treatment for proliferative diabetic retinopathies; however, this approach is ineffective in more than 30% of patients with diabetic retinal complications. Available evidence shows that subcutaneous (under the skin) injection of octreotide, a somatostatin analog, has potential t...